跳至主要内容
临床试验/NCT00519844
NCT00519844已完成4 期

Assessment of Satisfaction With Growth Hormone Treatment in Children Born Small for Gestational Age: Benefits of Galenic Form of the Product

Novo Nordisk A/S1 个研究点 分布在 1 个国家目标入组 5 人开始时间: 2005年7月最近更新:
适应症
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
5
试验地点
1
主要终点
Satisfaction/preference with the method of treatment assesses by means of a satisfaction questionnaire and a standard questionnaire of preference

研究概览

简要总结

This trial is conducted in Europe. The aim of this trial is to assess satisfaction with growth hormone treatment in children of both sexes born small for gestational age and who are receiving growth hormone treatment.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
6 Years 至 15 Years(Child)
性别
All
接受健康志愿者

入选标准

  • Children treated for 3 years with Maxomat® because of small for gestational age
  • Postnatal growth failure by the age of 3 years or more
  • No associated growth hormone deficiency
  • Height growth velocity greater than 2 cm/yr over the 12 month period preceding the inclusion
  • Bone age no more than 13 years for girls and no more than 15 years for boys

排除标准

  • Known, evolving tumour
  • Hypertrophic cardiomyopathy
  • Hypertension not controlled on maximum therapy
  • Benign intracranial hypertension
  • Known glucose intolerance or known diabetes mellitus
  • Acute or active chronic hepatitis
  • Chronic renal failure
  • Chromosomal and/or genetic syndromes (other than Silver-Russell syndrome) or abnormality

结局指标

主要结局

Satisfaction/preference with the method of treatment assesses by means of a satisfaction questionnaire and a standard questionnaire of preference

时间窗: after 3 months of treatment

次要结局

  • Tolerance of the treatment
  • Compliance
  • Biological (fasting glucose, fasting insulin, liver enzymes)
  • Clinical (adverse events)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

Growth Hormone Treatment in Children Born Small for... | 临床试验